Siliq

Active Ingredient(s): Brodalumab
FDA Approved: * February 15, 2017
Pharm Company: * VALEANT LUXEMBOURG
Category: Immune System

Brodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases.[1][2] In February 2017 it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.[3] Mechanism of action Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. This me... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Siliq 210 mg Subcutaneous Injection

NDC: 0187-0004

Labeler:

Valeant Pharmaceuticals North America LLC